Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Mar 23;10(4):398.
doi: 10.3390/nu10040398.

Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients

Evertine Wesselink  1 , Renate M Winkels  2 , Harm van Baar  3 , Anne J M R Geijsen  4 , Moniek van Zutphen  5 , Henk K van Halteren  6 , Bibi M E Hansson  7 , Sandra A Radema  8 , Johannes H W de Wilt  9 , Ellen Kampman  10 , Dieuwertje E G Kok  11
Affiliations
Observational Study

Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients

Evertine Wesselink et al. Nutrients. .

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe side-effect in colorectal cancer (CRC) patients. This study assessed the association between habitual dietary intake of magnesium or calcium and prevalence and severity of chronic CIPN in CRC patients receiving adjuvant chemotherapy. For this prospective cohort study, 196 CRC patients were considered. Magnesium and calcium intake was determined using a food frequency questionnaire at diagnosis, during and after chemotherapy. Chronic CIPN was assessed 12 months after diagnosis using the quality of life questionnaire CIPN20. Prevalence ratios were calculated to assess the association between magnesium or calcium intake and the prevalence of CIPN. Multivariable linear regression analysis was used to assess the association between magnesium or calcium intake and severity of CIPN. CIPN was reported by 160 (82%) patients. Magnesium intake during chemotherapy was statistically significantly associated with lower prevalence of CIPN (prevalence ratio (PR) 0.53, 95% confidence interval (CI) 0.32, 0.92). Furthermore, higher dietary intake of magnesium during (β -1.08, 95% CI -1.95, -0.22) and after chemotherapy (β -0.93, 95% CI -1.81, -0.06) was associated with less severe CIPN. No associations were found for calcium intake and the prevalence and severity of CIPN. To conclude, we observed an association between higher dietary magnesium intake and lower prevalence and severity of CIPN in CRC patients.

Keywords: calcium; chemotherapy; colorectal cancer; magnesium; neuropathy; oxaliplatin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Figures

Figure 1
Figure 1
Flowchart representing patient selection for the current study. Colorectal cancer patients participating in the longitudinal observational study on nutritional and lifestyle factors (the COLON study) and who received adjuvant chemotherapy and filled out the quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy (QLQ-CIPN16) were included in the present study. * Patients who were recruited before April 2012 were not included in this study, because the QLQ-CIPN16 questionnaire was implemented from April 2012 onwards.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat. Rev. 2008;34:368–377. doi: 10.1016/j.ctrv.2008.01.003. - DOI - PubMed
    1. Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-Induced Peripheral Neuropathy: A Current Review. Ann. Neurol. 2017;81:772–781. doi: 10.1002/ana.24951. - DOI - PMC - PubMed
    1. Vincenzi B., Frezza A.M., Schiavon G., Spoto C., Silvestris N., Addeo R., Catalano V., Graziano F., Santini D., Tonini G. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support. Care Cancer. 2013;21:1313–1319. doi: 10.1007/s00520-012-1667-5. - DOI - PubMed
    1. Attal N., Bouhassira D., Gautron M., Vaillant J.N., Mitry E., Lepère C., Rougier P., Guirimand F. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study. Pain. 2009;144:245–252. doi: 10.1016/j.pain.2009.03.024. - DOI - PubMed
    1. André T., de Gramont A., Vernerey D., Chibaudel B., Bonnetain F., Tijeras-Raballand A., Scriva A., Hickish T., Tabernero J., Van Laethem J.L., et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J. Clin. Oncol. 2015;33:4176–4187. doi: 10.1200/JCO.2015.63.4238. - DOI - PubMed

Publication types

MeSH terms